This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

27 Apr 2011

Inovio, Transgene and ChronTech Collaborate for HCV Vaccine

Each partner will contribute its products and equally share costs related to the study.

Inovio Pharmaceuticals has inked a deal with Transgene and ChronTech Pharma to jointly evaluate a therapeutic vaccination strategy against genotype 1 hepatitis C virus (HCV) in a phase I trial.


The clinical study, which will start later this year, is set to use ChronTech's ChronVac-C plasmid DNA vaccine delivered in vivo electroporation using Inovio's Medpulser DNA Delivery System (DDS) as the initial vaccination, followed by Transgene's therapeutic vaccine TG4040, a modified vaccinia Ankara (MVA).


Inovio's MedPulser DDS device delivers electrical pulses, enhancing cell membrane permeability, cellular uptake of the DNA vaccine and gene expression.


In previous tri

Related News